SFTPA1 variant carriers are at increased risk of inherited lung disease (Benusiglio et al., 2021), and this gene may be a viable prognostic biomarker since it is connected to immune cell infiltration and the effectiveness of immunotherapy in lung cancer (Yuan et al., 2022). This evidence concerns the gene SFTPA1 and lung cancer.